Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status

BACKGROUND: The human monoclonal antibody dupilumab blocks interleukin (IL)‐4 andIL‐13, key and central drivers of type 2 inflammation. Dupilumab, on background mometasone furoate nasal spray (MFNS), improved outcomes in the phase III SINUS‐52 study (NCT02898454) in patients with severe chronic rhin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujieda, Shigeharu, Matsune, Shoji, Takeno, Sachio, Ohta, Nobuo, Asako, Mikiya, Bachert, Claus, Inoue, Tomoyuki, Takahashi, Yoshinori, Fujita, Hiroyuki, Deniz, Yamo, Rowe, Paul, Ortiz, Benjamin, Li, Yongtao, Mannent, Leda P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290136/
https://www.ncbi.nlm.nih.gov/pubmed/33993501
http://dx.doi.org/10.1111/all.14906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290136/
https://www.ncbi.nlm.nih.gov/pubmed/33993501
http://dx.doi.org/10.1111/all.14906

Ejemplares similares